KRAS and familial pancreatic carcinoma: K-ras-activating mutations are an early event in pancreatic cancer and result in the activation of several downstream pathways among which are the Raf-MAPKs and the PI3K-Akt both having important cancer-promoting properties mediated by activation of procarcinogenic effectors or inhibition of tumor suppressors [61].